AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9363140
Drug: Fibrinolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic agents for promoting drainage of loculated, viscous pleural fluid
Trial: 6476587
Drug: Atropine sulphate
RxNorm normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine sulphate (18 mg nebulized during tidal breathing)
Trial: 30166639
Drug: High-fructose corn
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose corn syrup-sweetened beverages
Trial: 25069747
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) 75 mg/m² for 21 consecutive days followed by a 7-day rest for up to 6 cycles or until progression
Trial: 22372386
Drug: FP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP treatment
Trial: 16541716
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (control group).
Trial: 12971029
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg valdecoxib
Trial: 10052485
Drug: Verapamil SR
RxNorm normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil SR (360 mg)
Trial: 10052485
Drug: Vera/tran (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vera/tran (180 mg verapamil SR and 2 mg trandolapril)
Trial: 1787608
Drug: Fatty suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatty suppositories (FS)
Trial: 1787608
Drug: Gelatin capsulated
RxNorm normalized name: gelatin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsulated suppositories (GCS)
Trial: 7047770
Drug: Propranolol hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol hydrochloride (average dose, 105 mg)
Trial: 7047770
Drug: Clonidine hydrochloride
RxNorm normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine hydrochloride (0.24 mg)
Trial: 19237632
Drug: Denosumab (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (subcutaneous 180 mg every 4 weeks or every 12 weeks)
Trial: 16053664
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m² i.v. weekly for 6 weeks) + celecoxib (400 mg p.o. b.i.d. continuously)
Trial: 16053664
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel + celecoxib
Trial: 11988252
Drug: Alcohol-based hand
RxNorm normalized name: ALCOHOL 300 mL in 500 mL EXTRACORPOREAL GEL [JINHUI Alcohol-Based Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-based hand gels
Trial: 2656936
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1,000 mg of calcium carbonate daily for three months)
Trial: 29025850
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of tranexamic acid (TXA) intravenously
Trial: 22645023
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus delbrueckii subsp. bulgaricus 8481), 3 capsules per day for 6 months
Trial: 16469992
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid (EPA) at doses of 1.35, 2.7, or 4.05 g/d for 12 weeks
Trial: 15483809
Drug: Sequential method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential method including individual pressurization of each anchorage hole
Trial: 7850048
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefoxitin intravenously (n = 78)
Trial: 31462629
Drug: 100% orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% orange juice with 5 g of enzyme-treated orange pomace fiber (OPF)
Trial: 25598270
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (FA) in individuals with CC genotype for MTHFR C677T variant
Trial: 18080228
Drug: Topical or
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical or systemic corticosteroids
Trial: 18080228
Drug: Leukotriene receptor
RxNorm normalized name: Leukotriene receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukotriene receptor antagonists (montelukast)
Trial: 18080228
Drug: IL-5 blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-5 blockers (Mepolizumab)
Trial: 12653168
Drug: Dried hazelnut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried hazelnut (1 mg to 1 g hazelnut protein)
Trial: 12653168
Drug: Placebo doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo doses
Trial: 7927488
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 200 micrograms nasal spray twice daily for 6 weeks
Trial: 2582771
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 75 micrograms gestodene
Trial: 2582771
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 25 micrograms gestodene
Trial: 2582771
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 75 micrograms gestodene
Trial: 2582771
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 125 micrograms gestodene
Trial: 23603887
Drug: Gabapentin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (600 mg) plus dexamethasone (4 mg IV)
Trial: 23603887
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus dexamethasone (4 mg IV)
Trial: 21908768
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of HPV16/18 vaccine (Cervarix)
Trial: 21908768
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of HPV16/18 vaccine (Cervarix)
Trial: 21908768
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of HPV16/18 vaccine (Cervarix)
Trial: 17349072
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen (CEE; 0.625 mg/d)
Trial: 11808063
Drug: 25% aqueous
RxNorm normalized name: Glutaraldehyde 25% Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% aqueous extract of freshly prepared miswak solution
Trial: 7846263
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with radiotherapy to the primary tumor and CNS
Trial: 2899090
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (22 mU/m2.min)
Trial: 2899090
Drug: Insulin with
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin with SRIH (250 micrograms/h) and glucagon (0.4 ng/kg.min)
Trial: 28190980
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (0.03 g.kg.d‐1 during 14 d)
Trial: 16276705
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (Group A)
Trial: 16276705
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nebulized albuterol and furosemide (Group C)
Trial: 12045535
Drug: Erythropoietin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (600 U/kg) weekly for 3 weeks
Trial: 8577886
Drug: d‐amphetamine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine (5, 10 mg/70 kg, BID)
Trial: 8577886
Drug: d‐amphetamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine (30 mg/70 kg in four doses)
Trial: 9890307
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nifedipine
Trial: 29667330
Drug: TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF inhibitors (TNFI)
Trial: 29667330
Drug: Non-TNF inhibitors
RxNorm normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-TNF inhibitors (non-TNFI)
Trial: 29667330
Drug: Corticosteroids ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids ≥ 5 mg/day
Trial: 25111667
Drug: Nebulized combination
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized combination of salbutamol 1.875 mg/0.5 mL and ipratropium bromide 0.375 mg/0.5 mL
Trial: 22401327
Drug: Insulin-induced lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-induced lipid suppression
Trial: 22401327
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of Intralipid
Trial: 15856409
Drug: SJW (Esbericum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW (Esbericum capsules; 240 mg/die of extract, 3.5 mg hyperforin)
Trial: 1559951
Drug: High-Intensity Low-Volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Low-Volume Taper (HIT)
Trial: 1559951
Drug: Low-Intensity Moderate-Volume
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Moderate-Volume Taper (LIT)
Trial: 1559951
Drug: Rest-Only Taper
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest-Only Taper (ROT)
Trial: 3901772
Drug: +1.00 D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +1.00 D add treatment
Trial: 3901772
Drug: +2.00 D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +2.00 D add treatment
Trial: 3901772
Drug: Single vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vision (standard treatment)
Trial: 29455211
Drug: Intratympanic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratympanic dexamethasone (ITD) administered once weekly for 4 consecutive weeks
Trial: 26293380
Drug: Low-dose fludarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fludarabine with darbepoetin alfa
Trial: 26293380
Drug: Low-dose fludarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fludarabine without darbepoetin alfa
Trial: 21566199
Drug: R1663 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R1663 (oral factor Xa inhibitor)
Trial: 20645031
Drug: Routine adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine adjunctive manual thrombectomy devices
Trial: 10492259
Drug: Salmeterol (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (42 microg, twice-daily)
Trial: 1793366
Drug: Auranofin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (3 mg twice daily for 12 weeks)
Trial: 1793366
Drug: Inactive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo (3 mg twice daily for 12 weeks)
Trial: 19844115
Drug: Diet (balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet (balanced hypocaloric diet, weekly meetings with dietician)
Trial: 17220958
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy strategies
Trial: 10718384
Drug: Synchronous combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronous combination of band ligation and sclerotherapy
Trial: 9293051
Drug: clarithromycin suspension
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin suspension (7.5 mg/kg twice daily)
Trial: 9293051
Drug: amoxycillin syrup
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amoxycillin syrup (125 mg/kg three times daily for body weight < 25 kg, or 250 mg/kg three times daily for body weight 25 kg)
Trial: 3571860
Drug: Traditional Veterans
RxNorm normalized name: benzalkonium chloride Topical Foam [Veteran Shield 24]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Veterans Administration care
Trial: 27196663
Drug: Project AIM
RxNorm normalized name: Aimovig
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Project AIM (Adult Identity Mentoring) intervention, details on dosage and duration not specified.
Trial: 22464673
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with allergen tablets over a 4-month period
Trial: 12181464
Drug: 1% benzalkonium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% benzalkonium chloride (BC) vaginal suppository and bathing solution
Trial: 12181464
Drug: Placebo vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal suppository and bathing solution
Trial: 8038233
Drug: Conventional-dose Ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional-dose Ara-C (200 mg/m2 d 1-5) combined with idarubicin (12 mg/m2 d 1-3)
Trial: 8038233
Drug: Conventional-dose Ara-C/idarubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose Ara-C/idarubicin
Trial: 11570630
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor-I (IGF-I) levels measured in cerebrospinal fluid (CSF)
Trial: 29529897
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) 8 mg/kg/month for 6 months
Trial: 29529897
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (Conv)
Trial: 30104008
Drug: Local therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapies (LT)
Trial: 30104008
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy (MC)
Trial: 30650289
Drug: Olanzapine Tablet
RxNorm normalized name: Olanzapine Tablets
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine Tablet (OT)
Trial: 28676782
Drug: Thought Field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thought Field Therapy (TFT)
Trial: 16274999
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg/die)
Trial: 6127945
Drug: Verapamil (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (360 mg/day)
Trial: 28543041
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mean arterial pressure-guided therapy only)
Trial: 25657106
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy intervention (3 month programme)
Trial: 21907349
Drug: Theophylline plus
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline plus 0.5 L/min of room air via nasal prongs
Trial: 21907349
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 0.5 L/min with CO(2) (about 1% inhaled) by nasal prongs
Trial: 19506333
Drug: pHGF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pHGF treatment
Trial: 15138753
Drug: Piribedil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil (50 mg daily)
Trial: 12575393
Drug: Kuhuang Shenmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kuhuang Shenmai injection (KHSM) combined with Astragalus decoction (AD)
Trial: 12575393
Drug: Ribarvirin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribarvirin and ganlixin injection
Trial: 9627948
Drug: Intraarticular methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraarticular methotrexate (MTX) therapy (10 mg injections every 3 to 7 days)
Trial: 9627948
Drug: Intraarticular triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular triamcinolone hexacetonide (TC) therapy (40 mg single injection)
Trial: 26307566
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution (TrophAmine®)
Trial: 17487227
Drug: CX516 900
RxNorm normalized name: CX516
DrugBank: CX516 (DB06247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CX516 900 mg three times daily
Trial: 16492602
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) injections
Trial: 7249528
Drug: Placebo (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sodium chloride solution)
Trial: 11259736
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose loading (75 g)
Trial: 11127459
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose loading (75 g) + vitamins C (2 g) and E (800 IU)
Trial: 17768460
Drug: Esmolol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol infusion of 50‐250 ug.kg‐1.min‐1 after a bolus of 0.5 mgxkg‐1
Trial: 17768460
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion of 0.2‐0.5 ugxkg‐1xmin‐1
Trial: 16163242
Drug: New cytotoxic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cytotoxic agents and novel targeted therapies
Trial: 11071049
Drug: Salbutamol (Sal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (Sal, 6 mg)
Trial: 12439769
Drug: Caffeine (Caf,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (Caf, 250 mg)
Trial: 8645964
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.34 mg (kg body weight)‐1)
Trial: 8645964
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.31 mg (kg body weight)‐1)
Trial: 7324823
Drug: Rectal diazepam
RxNorm normalized name: diazepam Rectal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal diazepam (0.75 mg kg‐1)
Trial: 7324823
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of diazepam premedications and a small dose of lytic cocktail (pethidine, promethazine, chlorpromazine) given i.m. during anaesthesia
Trial: 6387616
Drug: Polymorphonuclear leukocyte
RxNorm normalized name: interferon alfa-3n,human leukocyte derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphonuclear leukocyte transfusions every 12 hours for a total of five transfusions (15 mL/kg per transfusion)
Trial: 23171244
Drug: 38% SDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% SDF treatment
Trial: 23171244
Drug: ART sealant
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART sealant treatment
Trial: 23171244
Drug: SDF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDF treatment
Trial: 20237046
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (500 μg via spacer device)
Trial: 15080014
Drug: Nicardipine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (starting dose 3 micrograms/kg per min)
Trial: 15080014
Drug: Nitroprusside (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside (starting dose 1 microgram/kg per min)